Valuation: Becton, Dickinson and Company

Market Cap 43.58B 38.09B 35.15B 32.4B 61.06B 4,197B 62.41B 420B 165B 2,056B 164B 160B 7,076B P/E 2026 *
39.4x
P/E 2027 * 30.4x
Enterprise Value 60.1B 52.52B 48.46B 44.67B 84.19B 5,787B 86.06B 579B 228B 2,834B 226B 221B 9,757B EV / Sales 2026 *
3.13x
EV / Sales 2027 * 2.92x
Free-Float
74.04%
Yield 2026 *
2.43%
Yield 2027 * 2.47%
Manager TitleAgeSince
Chief Executive Officer 53 28/01/2020
Director of Finance/CFO 44 05/12/2025
Chief Tech/Sci/R&D Officer - 29/11/2021
Director TitleAgeSince
Director/Board Member 65 26/03/2025
Director/Board Member 75 24/09/2002
Director/Board Member 71 26/07/2010
Change 5-day change 1-year change 3-year change Capi.($)
-.--%-18.36% - - 43.58B
+1.87%+7.19%-16.46%-5.91% 175B
-0.43%-0.80%-7.07%-4.05% 106B
-0.03%+1.47%+4.59%+60.25% 59.91B
+0.66%+0.96%+37.56%+53.38% 51.95B
-3.21%-3.05% - - 33.65B
-1.71%+2.25%-8.86%-44.23% 29.58B
-1.16%+1.28%+61.67%-6.62% 25.31B
-1.49%+0.85%-3.01%-4.60% 21.23B
-0.91%+1.31%-3.73%-18.94% 20.68B
Average -0.64%+1.27%+8.09%+3.66% 58.24B
Weighted average by Cap. +0.13%+2.59%-0.52%+6.01%

Financials

2026 *2027 *
Net sales 19.21B 16.79B 15.49B 14.28B 26.92B 1,850B 27.52B 185B 72.84B 906B 72.16B 70.57B 3,120B 19.73B 17.24B 15.91B 14.66B 27.63B 1,900B 28.25B 190B 74.78B 930B 74.08B 72.45B 3,203B
Net income 1.12B 983M 907M 836M 1.58B 108B 1.61B 10.84B 4.26B 53.04B 4.22B 4.13B 183B 1.45B 1.27B 1.17B 1.08B 2.03B 140B 2.08B 13.97B 5.49B 68.35B 5.44B 5.32B 235B
Net Debt 16.51B 14.43B 13.32B 12.28B 23.14B 1,590B 23.65B 159B 62.61B 779B 62.02B 60.66B 2,681B 13.96B 12.2B 11.26B 10.37B 19.55B 1,344B 19.99B 135B 52.92B 658B 52.42B 51.27B 2,266B
Logo Becton, Dickinson and Company
Becton, Dickinson and Company specializes in the development, manufacturing and marketing of medical and diagnostic equipment and materials. Net sales break down by family of products as follows: - medical management systems (52.4%): medication delivery systems, pharmaceutical systems, advanced patient monitoring systems, etc.; - interventional medical equipment (23.9%): surgical instruments, urological care products, etc.; - diagnostic materials and clinical research and development tools (23.7%): automated systems for blood testing, mycobacteria detection, and molecular biology, medical biology devices, tools for studying genes and culturing cells, instruments for sorting and analyzing cells, monoclonal antibodies, etc. Net sales are distributed geographically as follows: the United States (58.6%), Europe/Middle East/Africa (21.6%), Asia (14.2%) and other (5.6%).
Employees
-
Trader
Investor
Global
Quality
ESG MSCI
A